Hypophosphatasia (HPP) is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.
In this exclusive interview with Rare Disease Report, Martin Mackay, PHD, global head of research and development at Alexion Pharmaceuticals talks about this ultra rare and devastating genetic condition.
